Physician profile
Sandeep Kumar Thaper
NPI 1881627966
$21,872.43
in general payments reported to CMS, 2019-2025
81 companies · $3,465 in 2025
The $3,465 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,328 · 2020: $2,330 · 2021: $2,838 · 2022: $2,931 · 2023: $3,019 · 2024: $3,962 · 2025: $3,465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,145.94 |
| Education | $299.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,451.06 | 2019-2025 | Rybrevant, Erleada, Carvykti |
| Merck Sharp & Dohme LLC | $1,434.44 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,430.43 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,227.55 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Genzyme Corporation | $1,007.35 | 2019-2025 | |
| Celgene Corporation | $1,006.53 | 2020-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $1,002.61 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Pfizer INC. | $991.11 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $913.55 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Amgen INC. | $661.50 | 2019-2025 | |
| Seagen INC. | $652.40 | 2019-2023 | Adcetris, Tukysa, Tivdak |
| Astellas Pharma US INC | $578.22 | 2019-2025 | Vyloy, Padcev, Xospata |
| Daiichi Sankyo INC. | $554.72 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Genentech USA, INC. | $530.96 | 2019-2025 | Tecentriq, Polivy, Alecensa |
| Lilly USA, LLC | $521.73 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Thaper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.